ROBIN MANSOLINO: Open Payments
NPI 1326546755 · LAKELAND, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$436 in 21 payments from 10 companies in 2025. Trend: 2023 $40 · 2024 $107 · 2025 $436
Food & beverage: $436
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 3 | $76 |
| Teva Pharmaceuticals USA, Inc. | 4 | $75 |
| Axsome Therapeutics, Inc. | 3 | $64 |
| ABBVIE INC. | 3 | $64 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Lundbeck LLC | 2 | $38 |
| Corium, LLC | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
Products named: ARISTADA, AUSTEDO XR, Auvelity, VRAYLAR, REXULTI, CAPLYTA, Azstarys, COBENFY.
Industry payments across FL — which companies pay providers there.
